Skip to main content
. Author manuscript; available in PMC: 2010 Jun 2.
Published in final edited form as: Mol Med Rep. 2008 Jul;1(4):589–594.

Figure 2.

Figure 2

Slot blot analysis of three representative ovarian cancer sera. Each blot represents a duplicate test for autoantibodies against a panel of eleven recombinant cancer antigens, with phosphate-buffered saline (PBS) as a negative control. Lane 1, PBS; lane 2, survivin; lane 3, p53; lane 4, p16; lane 5, cyclin B1; lane 6, cyclin D1; lane 7, cyclin E; lane 8, Koc; lane 9, Imp1; lane 10, p62; lane 11, CDK2; lane 12, c-Myc. (A) Normal human serum shows no reactivity to any of the eleven TAAs. (B) One ovarian cancer serum shows strong reactivity to just CDK2. (C) Another ovarian cancer serum shows reactivity to Imp1 and CDK2. (D) A third ovarian cancer serum shows strong reactivity to p16, p62 and c-myc, and weak reactivity to survivin, p53, cyclin B1, Imp1 and CDK2.